NCT04522375View on ClinicalTrials.gov

A Dose Escalation Study of FP-045 in Patients With Fanconi Anemia

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Fanconi Anemia
Interventions
DRUG

FP-045

activator of aldehyde dehydrogenase

Sponsors
All Listed Sponsors
lead

Foresee Pharmaceuticals Co., Ltd.

INDUSTRY